Table 4.
Peak oxygen uptake (mL·kg-0.61.min-1) |
Peak oxygen uptake (mL·FFM-1.min-1) |
|||
---|---|---|---|---|
Lower | Higher | Lower | Higher | |
BMI (kg·m-2) | 17.8 ± 2.9 (n=48) | 16.8 ± 1.6 (n=48) | 17.4 ± 2.38 (n=43) | 17.1 ± 2.43 (n=53) |
TBF% | 19.5 ± 9.6 (n=43) | 16.2 ± 6.7 (n=43) | 16.2 ± 8.7 (n=43) | 19.6 ± 7.8 (n=43) |
VAT (cm3) | 131.1 ± 86.4 (n=42) | 109.8 ± 63.6 (n=44) | 118.0 ± 60.2 (n=38) | 121.9 ± 86.9 (n=48) |
Total cholesterol (mmol·L-1) | 4.57 ± 0.66 (n=38) | 4.45 ± 0.73 (n=41) | 4.39 ± 0.63 (n=37) | 4.61 ± 0.74 (n=42) |
HDL-C (mmol·L-1) | 1.86 ± 0.44 (n=38) | 1.86 ± 0.41 (n=40) | 1.79 ± 0.40 (n=37) | 1.92 ± 0.44 (n=41) |
LDL-C (mmol·L-1) | 2.34 ± 0.59 (n=38) | 2.24 ± 0.60 (n=40) | 2.24 ± 0.55 (n=37) | 2.33 ± 0.63 (n=41) |
TG (mmol·L-1) | 0.81 ± 0.31 (n=38) | 0.79 ± 0.28 (n=40) | 0.78 ± 0.32 (n=37) | 0.81 ± 0.28 (n=41) |
Glucose (mmol.L-1) | 4.38 ± 0.33 (n=38) | 4.29 ± 0.42 (n=42) | 4.37 ± 0.38 (n=37) | 4.30 ± 0.39 (n=43) |
Specific insulin (pmol·L-1) | 45.1 ± 24.3 (n=35) | 51.0 ± 25.7 (n=34) | 43.4 ± 21.9 (n=36) | 53.1 ± 27.5 (n=33) |
β-cell function (%) | 118.1 ± 44.7 (n=35) | 130.4 ± 47.5 (n=34) | 113.2 ± 35.2 (n=36) | 136.2 ± 53.8 (n=33) |
HOMA-IS (%) | 153.7 ± 98.9 (n=35) | 127.0 ± 71.9 (n=34) | 157.3 ± 101.3 (n=36) | 122.4 ± 65.0 (n=33) |
HOMA-IR | 0.92 ± 0.49 (n=35) | 1.04 ± 0.51 (n=34) | 0.89 ± 0.45 (n=36) | 1.07 ± 0.55 (n=33) |
Sample size (n=) is provided for each outcome. BMI - body mass index; TBF% - total body fat percentage; VAT - visceral adipose tissue; HDL-C - high density lipoprotein cholesterol; LDL-C – low density lipoprotein cholesterol; TG -Triglyceride; HOMA – Homeostatic model assessment; IS – Insulin sensitivity; IR – Insulin resistance. TBF% was entered as a covariate for the specific insulin, β-cell function, HOMA-IS and HOMA-IR outcomes.